INTRODUCTION: The efficacy of non-invasive ultrasound skin tightening (e.g., Sofwave) relies on fibroblast mechanotransduction, a process impaired in obesity. The widespread use of GLP-1 receptor agonists (GLP-1RAs) like semaglutide for weight loss introduces a dynamic metabolic variable that may further alter dermal tissue state. The optimal timing between these interventions is unknown and difficult to study clinically.
METHODS: We conducted a first fully computational, mechanistically constrained virtual randomized trial. A cohort of 20,000 digital twins (BMI >30 kg/m) was randomized across five arms receiving identical Sofwave schedules, but varying semaglutide start times (concurrent, 1, 3, or 6 months pre-treatment, vs. Sofwave-only). The multiscale model coupled a finite element model of ultrasound-induced tissue stress with an agent-based model of fibroblast dynamics, ECM remodelling, and semaglutide pharmacodynamics. The primary endpoint was the time-integrated cycling fibroblast burden (AUC). 2
RESULTS: Fibroblast response to identical mechanical stress was gated by insulin resistance (IR). Higher IR raised the activation threshold from 36.8 to 47.9 kPa and reduced max cycling probability from 0.34 to 0.21. Semaglutide timing created a non-monotonic effect: 3-month pre-treatment yielded the greatest net benefit (+0.092 cycling AUC, +41% collagen density). This benefit resulted from balancing direct fibroblast priming (+0.118 AUC) against indirect adipose support loss (-0.026 AUC). Prolonged (6-month) pre-treatment was detrimental in high-IR phenotypes (90th percentile ΔAUC: -0.006). The 3-month pre-treatment arm also produced a more isotropic ECM (anisotropy index: 0.26 vs. 0.41 in control).
CONCLUSION: Sofwave's remodelling efficacy is determined by tissue mechanosensitivity, which is dynamically and non-uniformly modulated by GLP-1RA therapy. These simulations identify a potential therapeutic window, suggesting that initiating mechanical stimulation during early metabolic improvement but before significant adipose support loss may optimize dermal outcomes in obese patients. These computational findings are hypothesis-generating and require experimental validation through ex vivo and clinical studies before clinical translation.
LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
